248 related articles for article (PubMed ID: 8996263)
1. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis.
Kasteler JS; Callen JP
J Am Acad Dermatol; 1997 Jan; 36(1):67-71. PubMed ID: 8996263
[TBL] [Abstract][Full Text] [Related]
2. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.
Ruperto N; Pistorio A; Oliveira S; Zulian F; Cuttica R; Ravelli A; Fischbach M; Magnusson B; Sterba G; Avcin T; Brochard K; Corona F; Dressler F; Gerloni V; Apaz MT; Bracaglia C; Cespedes-Cruz A; Cimaz R; Couillault G; Joos R; Quartier P; Russo R; Tardieu M; Wulffraat N; Bica B; Dolezalova P; Ferriani V; Flato B; Bernard-Medina AG; Herlin T; Trachana M; Meini A; Allain-Launay E; Pilkington C; Vargova V; Wouters C; Angioloni S; Martini A;
Lancet; 2016 Feb; 387(10019):671-678. PubMed ID: 26645190
[TBL] [Abstract][Full Text] [Related]
3. Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis.
Sinoway PA; Callen JP
Arthritis Rheum; 1993 Mar; 36(3):319-24. PubMed ID: 8452575
[TBL] [Abstract][Full Text] [Related]
4. The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients.
Giancane G; Lavarello C; Pistorio A; Oliveira SK; Zulian F; Cuttica R; Fischbach M; Magnusson B; Pastore S; Marini R; Martino S; Pagnier A; Soler C; Staņēvicha V; Ten Cate R; Uziel Y; Vojinovic J; Fueri E; Ravelli A; Martini A; Ruperto N;
Pediatr Rheumatol Online J; 2019 May; 17(1):24. PubMed ID: 31118099
[TBL] [Abstract][Full Text] [Related]
5. [Panniculitis in patient undergoing treatment for dermatomyositis with methotrexate].
Feki NB; Khanfir MS; Ghorbel IB; Said F; Houman MH
Pan Afr Med J; 2016; 23():149. PubMed ID: 27279974
[TBL] [Abstract][Full Text] [Related]
6. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine.
Schiopu E; Phillips K; MacDonald PM; Crofford LJ; Somers EC
Arthritis Res Ther; 2012 Jan; 14(1):R22. PubMed ID: 22284862
[TBL] [Abstract][Full Text] [Related]
7. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid.
Heilborn JD; Ståhle-Bäckdahl M; Albertioni F; Vassilaki I; Peterson C; Stephansson E
J Am Acad Dermatol; 1999 May; 40(5 Pt 1):741-9. PubMed ID: 10321603
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapeutic management of pulmonary sarcoidosis.
Fazzi P
Am J Respir Med; 2003; 2(4):311-20. PubMed ID: 14719997
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate and corticosteroid therapy for pediatric localized scleroderma.
Uziel Y; Feldman BM; Krafchik BR; Yeung RS; Laxer RM
J Pediatr; 2000 Jan; 136(1):91-5. PubMed ID: 10636981
[TBL] [Abstract][Full Text] [Related]
10. The use of pulse corticosteroid therapy for juvenile dermatomyositis.
Paller AS
Pediatr Dermatol; 1996; 13(4):347-8. PubMed ID: 8844758
[No Abstract] [Full Text] [Related]
11. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L;
N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic strategies in idiopatic inflammatory myopathies].
Chakour R; Leimgruber A; Bart PA; Spertini F
Rev Med Suisse; 2009 Apr; 5(199):812-8. PubMed ID: 19441746
[TBL] [Abstract][Full Text] [Related]
13. [Can we predict the risk of malignancy associated with dermatomyositis?].
Gainon J; Bart PA; Waeber G
Praxis (Bern 1994); 2003 Oct; 92(41):1734-9. PubMed ID: 14587367
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate and azathioprine treatment of childhood dermatomyositis.
Jacobs JC
Pediatrics; 1977 Feb; 59(2):212-8. PubMed ID: 299938
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids.
Ramanan AV; Campbell-Webster N; Ota S; Parker S; Tran D; Tyrrell PN; Cameron B; Spiegel L; Schneider R; Laxer RM; Silverman ED; Feldman BM
Arthritis Rheum; 2005 Nov; 52(11):3570-8. PubMed ID: 16255046
[TBL] [Abstract][Full Text] [Related]
16. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid.
Paul MA; Jorizzo JL; Fleischer AB; White WL
J Am Acad Dermatol; 1994 Oct; 31(4):620-5. PubMed ID: 8089289
[TBL] [Abstract][Full Text] [Related]
17. Leflunomide as adjuvant treatment of dermatomyositis.
Boswell JS; Costner MI
J Am Acad Dermatol; 2008 Mar; 58(3):403-6. PubMed ID: 18194823
[TBL] [Abstract][Full Text] [Related]
18. The PRINTO juvenile dermatomyositis trial.
Dale A; Milosevic I; Goldacre B;
Lancet; 2016 Jun; 387(10038):2600-2601. PubMed ID: 27353816
[No Abstract] [Full Text] [Related]
19. The PRINTO juvenile dermatomyositis trial - Authors' reply.
Ruperto N; Pistorio A; Ravelli A; Angioloni S; Martini A;
Lancet; 2016 Jun; 387(10038):2601. PubMed ID: 27353819
[No Abstract] [Full Text] [Related]
20. Pharmacological management of dermatomyositis.
Griger Z; Nagy-Vincze M; Dankó K
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1109-1118. PubMed ID: 28691537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
